Switch to:
Also traded in: France, Germany, Italy, Mexico, Switzerland, UK, USA

Latest Guru Trades with SNY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:NYSE:JNJ, NYSE:PFE, XSWX:NOVN, NYSE:MRK, NYSE:BMY » details
Traded in other countries:SAN.France, SNW.Germany, SANF.Italy, SNYN.Mexico, SAN.Switzerland, 0O59.UK, SNYNF.USA,
Sanofi SA is a healthcare company, engaged in the research, development, manufacture and marketing of healthcare products.

Sanofi SA was incorporated under the laws of France on April 28,1994 as a société anonyme, a form of limited liability company. It is a healthcare company, engaged in the research, development, manufacture and marketing of healthcare products. Its principal activities include Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. It also operates through the following platforms: Emerging Markets, Diabetes Solutions, Vaccines, Consumer Health Care (CHC), Animal Health, Genzyme, and Other Innovative Products. The Pharmaceuticals segment covers research, development, production and marketing of medicines, including activities acquired with Genzyme. Sanofi's pharmaceuticals portfolio consists of flagship products, plus prescription medicines, generic medicines, and consumer health products. This segment also includes all associates and joint ventures whose activities are related to pharmaceuticals, in particular the entities majority owned by BMS. The Vaccines segment is wholly dedicated to vaccines, including research, development, production and marketing. This segment includes Sanofi Pasteur MSD joint venture with Merck & Co., Inc. in Europe. The Animal Health segment comprises the research, development, production and marketing activities of Merial, which offers medicines and vaccines for a wide variety of animal species. Its competitors include Novo Nordisk, Merck, Eli Lilly, Bristol-Myers Squibb, GlaxoSmithKline, Novartis, Shire, Pfizer, Biogen Idec, Teva and Merck Serono, Bayer, Roche, Johnson & Johnson, AstraZeneca, Boehringer-Ingelheim, Fresenius Medical Care, among others. The Company's products and manufacturing facilities are subject to significant government regulations and approvals.

Top Ranked Articles about Sanofi SA

Sanofi's New Products Will Fuel Sales Company is developing vaccine for Zika virus
One of the most prominent stocks that most investors like to keep in their portfolios is Sanofi. (NYSE:SNY). Among the gurus, James Barrow (Trades, Portfolio) is one of the largest shareholders of the stock and some of the other prominent investors who hold a position in Sanofi are Ken Fisher (Trades, Portfolio), Bill Nygren (Trades, Portfolio) and Warren Buffett. Read more...
Weekly 3-Year Low Highlights: Sanofi, Exelon, Cummins, W.W. Grainger A look at companies whose stocks have recently reached their 3-year lows
According to GuruFocus list of 3-year lows, Sanofi (NYSE:SNY), Exelon Corp. (NYSE:EXC), Cummins Inc. (NYSE:CMI) and W.W. Grainger Inc. (NYSE:GWW) have all reached their three-year lows. Read more...
John Buckingham Buys 10 New Stakes in Second Quarter
John Buckingham (Trades, Portfolio), chief investment officer of AFAM (Al Frank Asset Management) Capital, which specializes in managing exchange-traded funds and equity portfolios, and editor of The Prudent Investor, an investment newsletter, learned the ropes from value investor Al Frank. The Al Frank Fund posted returns of 5.47% in 2014, 37.06% in 2013 and 17.26% in 2012. Read more...
» More Articles for SNY

Ratios

vs
industry
vs
history
P/E(ttm) 22.20
SNY's P/E(ttm) is ranked higher than
62% of the 558 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.44 vs. SNY: 22.20 )
Ranked among companies with meaningful P/E(ttm) only.
SNY' s P/E(ttm) Range Over the Past 10 Years
Min: 9.64  Med: 20.89 Max: 38.97
Current: 22.2
9.64
38.97
Forward P/E 12.95
SNY's Forward P/E is ranked higher than
58% of the 90 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.95 vs. SNY: 12.95 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 22.20
SNY's PE(NRI) is ranked higher than
63% of the 549 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.81 vs. SNY: 22.20 )
Ranked among companies with meaningful PE(NRI) only.
SNY' s PE(NRI) Range Over the Past 10 Years
Min: 9.82  Med: 20.93 Max: 39.2
Current: 22.2
9.82
39.2
P/B 1.62
SNY's P/B is ranked higher than
72% of the 762 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.80 vs. SNY: 1.62 )
Ranked among companies with meaningful P/B only.
SNY' s P/B Range Over the Past 10 Years
Min: 1.11  Med: 1.69 Max: 2.38
Current: 1.62
1.11
2.38
P/S 2.77
SNY's P/S is ranked higher than
51% of the 714 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.76 vs. SNY: 2.77 )
Ranked among companies with meaningful P/S only.
SNY' s P/S Range Over the Past 10 Years
Min: 1.72  Med: 2.81 Max: 3.94
Current: 2.77
1.72
3.94
EV-to-EBIT 17.84
SNY's EV-to-EBIT is ranked higher than
58% of the 537 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.64 vs. SNY: 17.84 )
Ranked among companies with meaningful EV-to-EBIT only.
SNY' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.3  Med: 19.30 Max: 200.9
Current: 17.84
8.3
200.9
EV-to-EBITDA 13.02
SNY's EV-to-EBITDA is ranked higher than
66% of the 569 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.81 vs. SNY: 13.02 )
Ranked among companies with meaningful EV-to-EBITDA only.
SNY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.4  Med: 12.80 Max: 129.7
Current: 13.02
5.4
129.7
Shiller P/E 20.47
SNY's Shiller P/E is ranked higher than
82% of the 146 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 46.77 vs. SNY: 20.47 )
Ranked among companies with meaningful Shiller P/E only.
SNY' s Shiller P/E Range Over the Past 10 Years
Min: 12.53  Med: 21.29 Max: 28.21
Current: 20.47
12.53
28.21
Current Ratio 1.72
SNY's Current Ratio is ranked lower than
66% of the 662 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.40 vs. SNY: 1.72 )
Ranked among companies with meaningful Current Ratio only.
SNY' s Current Ratio Range Over the Past 10 Years
Min: 0.79  Med: 1.72 Max: 2.71
Current: 1.72
0.79
2.71
Quick Ratio 1.36
SNY's Quick Ratio is ranked lower than
65% of the 662 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.87 vs. SNY: 1.36 )
Ranked among companies with meaningful Quick Ratio only.
SNY' s Quick Ratio Range Over the Past 10 Years
Min: 0.46  Med: 1.26 Max: 2.41
Current: 1.36
0.46
2.41
Days Inventory 139.55
SNY's Days Inventory is ranked lower than
63% of the 668 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.30 vs. SNY: 139.55 )
Ranked among companies with meaningful Days Inventory only.
SNY' s Days Inventory Range Over the Past 10 Years
Min: 170.45  Med: 192.11 Max: 378.14
Current: 139.55
170.45
378.14
Days Sales Outstanding 79.53
SNY's Days Sales Outstanding is ranked lower than
55% of the 620 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 74.15 vs. SNY: 79.53 )
Ranked among companies with meaningful Days Sales Outstanding only.
SNY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 61.19  Med: 74.14 Max: 83.73
Current: 79.53
61.19
83.73
Days Payable 131.68
SNY's Days Payable is ranked higher than
79% of the 589 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 71.47 vs. SNY: 131.68 )
Ranked among companies with meaningful Days Payable only.
SNY' s Days Payable Range Over the Past 10 Years
Min: 99.74  Med: 125.26 Max: 326.59
Current: 131.68
99.74
326.59

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 4.03
SNY's Dividend Yield is ranked higher than
89% of the 585 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.50 vs. SNY: 4.03 )
Ranked among companies with meaningful Dividend Yield only.
SNY' s Dividend Yield Range Over the Past 10 Years
Min: 1.7  Med: 3.70 Max: 5.46
Current: 4.03
1.7
5.46
Dividend Payout 0.87
SNY's Dividend Payout is ranked lower than
87% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.33 vs. SNY: 0.87 )
Ranked among companies with meaningful Dividend Payout only.
SNY' s Dividend Payout Range Over the Past 10 Years
Min: 0.27  Med: 0.62 Max: 1
Current: 0.87
0.27
1
Dividend Growth (3y) 2.50
SNY's Dividend Growth (3y) is ranked lower than
62% of the 283 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.70 vs. SNY: 2.50 )
Ranked among companies with meaningful Dividend Growth (3y) only.
SNY' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 6.45 Max: 29.6
Current: 2.5
0
29.6
Forward Dividend Yield 4.05
SNY's Forward Dividend Yield is ranked higher than
87% of the 568 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.62 vs. SNY: 4.05 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 4.81
SNY's Yield on cost (5-Year) is ranked higher than
83% of the 709 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.95 vs. SNY: 4.81 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
SNY' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 2.03  Med: 4.42 Max: 6.52
Current: 4.81
2.03
6.52
3-Year Average Share Buyback Ratio 0.90
SNY's 3-Year Average Share Buyback Ratio is ranked higher than
91% of the 425 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.40 vs. SNY: 0.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SNY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -24.5  Med: 0.00 Max: 2.2
Current: 0.9
-24.5
2.2

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 14.84
SNY's Price/Tangible Book is ranked lower than
92% of the 708 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.38 vs. SNY: 14.84 )
Ranked among companies with meaningful Price/Tangible Book only.
SNY' s Price/Tangible Book Range Over the Past 10 Years
Min: 7.22  Med: 14.15 Max: 41.94
Current: 14.84
7.22
41.94
Price/Projected FCF 4.04
SNY's Price/Projected FCF is ranked higher than
76% of the 311 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.53 vs. SNY: 4.04 )
Ranked among companies with meaningful Price/Projected FCF only.
SNY' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.92  Med: 1.23 Max: 1.56
Current: 4.04
0.92
1.56
Price/Median PS Value 0.99
SNY's Price/Median PS Value is ranked higher than
63% of the 680 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.09 vs. SNY: 0.99 )
Ranked among companies with meaningful Price/Median PS Value only.
SNY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.64  Med: 1.08 Max: 2.69
Current: 0.99
0.64
2.69
Price/Graham Number 3.86
SNY's Price/Graham Number is ranked lower than
76% of the 432 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.10 vs. SNY: 3.86 )
Ranked among companies with meaningful Price/Graham Number only.
SNY' s Price/Graham Number Range Over the Past 10 Years
Min: 1.99  Med: 4.34 Max: 6.54
Current: 3.86
1.99
6.54
Earnings Yield (Greenblatt) (%) 5.60
SNY's Earnings Yield (Greenblatt) (%) is ranked higher than
71% of the 782 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.00 vs. SNY: 5.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SNY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.5  Med: 5.20 Max: 12
Current: 5.6
0.5
12
Forward Rate of Return (Yacktman) (%) -3.94
SNY's Forward Rate of Return (Yacktman) (%) is ranked lower than
72% of the 323 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.36 vs. SNY: -3.94 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
SNY' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -6.1  Med: 16.80 Max: 44.3
Current: -3.94
-6.1
44.3

More Statistics

Revenue (TTM) (Mil) $37,751
EPS (TTM) $ 1.85
Beta1.01
Short Percentage of Float0.20%
52-Week Range $37.63 - 54.98
Shares Outstanding (Mil)2,611.39

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 40,508 40,718 43,695
EPS ($) 3.01 3.05 3.37
EPS without NRI ($) 3.01 3.05 3.37
EPS Growth Rate
(3Y to 5Y Estimate)
2.44%
» More Articles for SNY

Headlines

Articles On GuruFocus.com
Endonovo Therapeutics: Innovative Treatment, Catalyst Create Compelling Opportunity May 22 2016 
Charles Brandes Trims Stake in South American Petroleum Company May 13 2016 
Warren Buffett’s Top 5 Dividend Yielding Stocks Apr 26 2016 
Manning & Napier Sells Chunks of Stakes in GE, Eli Lilly, Merck Mar 29 2016 
Amgen: Should I Just Sit and Wait? Mar 18 2016 
Sanofi's New Products Will Fuel Sales Mar 13 2016 
Warren Buffett's Worst Performing Stocks Mar 03 2016 
Dodge & Cox Global Stock Fund 4th Quarter Commentary Jan 19 2016 
Dodge & Cox Stock Fund 2015 Commentary Jan 18 2016 
Why MannKind Could Be a Value Trap Jan 04 2016 

More From Other Websites
Dealpolitik: Medivation's 'Just Say No' Strategy May Be in Trouble May 27 2016
Medivation Fires Back Following Sanofi's Board Proposal May 27 2016
How Medivation Shareholders May Lose Big by Poison Pill in Hostile Takeover Fight With Sanofi May 26 2016
Sanofi's Diabetes Drug Combination Wins FDA Panel Backing May 26 2016
2:44 am Sanofi receives FDA recommendation of NDA for treatment for adults with Type 2 diabetes May 26 2016
[$$] Sanofi Moves to Replace Medivation Board May 25 2016
FDA Advisory Committee Recommends Approval of Sanofi Treatment for Adults with Type 2 Diabetes May 25 2016
Medivation: Three Biotech Giants Enter. Which One Leaves? May 25 2016
Stocks climb for the second day as energy companies jump May 25 2016
Sanofi moves to oust Medivation board in $9.3 billion takeover fight May 25 2016
Sanofi moves to oust Medivation board in $9.3 billion takeover fight May 25 2016
Sanofi moves to oust Medivation board in $9.3 bln takeover fight May 25 2016
U.S. panel backs approval of Sanofi combination diabetes drug May 25 2016
Sanofi Moves To Replace Medivation’s Board As New Buyers Rumored May 25 2016
Alnylam Soars as Drugmakers Circle Rival Biotechnology Company May 25 2016
[$$] Sanofi Moves to Replace Medivation Board May 25 2016
[$$] Sanofi seeks to oust entire Medivation board May 25 2016
Why Sanofi SA (ADR) (SNY) Is Trending on Wednesday May 25 2016
Sanofi Plays Game of Chicken With Medivation May 25 2016
Major Developments for Sanofi in 1Q16 May 25 2016
Sanofi wants to dump Medivation's board after rejected deal May 25 2016
Sanofi wants to dump Medivation's board after rejected deal May 25 2016
France's Sanofi seeks to sack board of US takeover prey May 25 2016
French drugmaker Sanofi to step up push into China May 25 2016
Exclusive - Sanofi to unveil challenge to Medivation's board: sources May 24 2016
France's Sanofi seeks to sack board of US takeover prey May 24 2016
FDA staff question usefulness of Sanofi diabetes drugs May 23 2016
Sanofi's executive VP for diabetes to leave company May 23 2016
FDA staff question dosing of Sanofi combination diabetes drug May 23 2016
ALK appoints Carsten Hellmann as new President and CEO May 17 2016
Sanofi Files for Hart-Scott-Rodino Notification Regarding Proposed Acquisition of Medivation May 12 2016
Sanofi recalls some batches of painkiller Combiflam in India May 12 2016
Sanofi recalls some batches of painkiller Combiflam in India May 12 2016
Medivation succumbs to pressure to explore sale - sources May 10 2016
Exclusive - Medivation succumbs to pressure to explore sale: sources May 09 2016
Sanofi ready to up offer for drugmaker Medivation, could oust board May 05 2016
Sanofi, Amgen cholesterol drugs win UK backing after price cuts May 05 2016
Sanofi presses drugmaker Medivation to take $9.3B offer May 05 2016
Sanofi Sends Letter to Medivation's Board of Directors May 05 2016
Sanofi: Annual General Shareholder Meeting of May 4, 2016 May 04 2016
EXCLUSIVE: Pfizer approaches Medivation about potential takeover -sources May 03 2016
EXCLUSIVE: Pfizer approaches Medivation about potential takeover -sources May 03 2016
French drug giant Sanofi vows hostile bid for US prey Apr 29 2016
Sanofi, Medivation dig in for big biotech takeover battle Apr 29 2016
Medivation rejects Sanofi bid, Sanofi to go to shareholders Apr 29 2016
US biotech firm Medivation rejects Sanofi takeover bid Apr 29 2016
Medivation board rejects Sanofi's $9.3 billion takeover offer Apr 29 2016
Sanofi says committed to Medivation takeover Apr 29 2016
Eurozone growth fails to stir stock markets Apr 29 2016
French drug giant Sanofi vows hostile bid for US prey Apr 29 2016
Sanofi profits stable, strong sales in emerging markets Apr 29 2016
Sanofi: Solid Performance in the First Quarter of 2016 with Business EPS(1) up 5.3% at Constant... Apr 29 2016
US biotech firm Medivation rejects Sanofi takeover bid Apr 28 2016
Deals of the day- Mergers and acquisitions Apr 28 2016
France's Sanofi makes $9.3 billion bid for US cancer drug giant Apr 28 2016
Sanofi launches $9.3 billion fight for U.S. cancer firm Medivation Apr 28 2016
Sanofi launches $9.3 bln fight for U.S. cancer firm Medivation Apr 28 2016
Sanofi makes $9.3 billion bid for American firm Medivation Apr 28 2016
BUZZ-Medivation: Sanofi makes $9.3 bln bid Apr 28 2016
Sanofi makes $9.3 bn offer for cancer drug firm Medivation Apr 28 2016
France's Sanofi makes $9.3 billion bid for US cancer drug giant Apr 28 2016
Sanofi : Sanofi Offers to Acquire Medivation for $52.50 Per Share in Cash Apr 28 2016
Sanofi makes $9.3 bn offer for cancer drug firm Medivation Apr 27 2016
UK agency backs cancer drug after Sanofi cuts price Apr 21 2016
Breakthrough cholesterol drugs fizzle amid price pushback Apr 20 2016
Sanofi Invests €300 Million To Expand Biologics Site in Belgium Apr 19 2016
OFFICIAL-UPDATE 1-WHO group backs Sanofi's vaccine in areas with high dengue rates Apr 15 2016
WHO group backs Sanofi's vaccine in areas with high dengue rates Apr 15 2016
Strategic Advisory Group of Experts on Immunization Convened by the World Health Organization... Apr 15 2016
Sanofi: Availability of the Pre-quarterly Results Communication Apr 08 2016
Technavio Announces Top Six Vendors in the Global Consumer Healthcare Market Until 2020 Apr 07 2016
Sanofi: World's First Public Dengue Immunization Program Starts in the Philippines Apr 04 2016
Regeneron and Sanofi Announce Positive Dupilumab Topline Results from Two Phase 3 Trials in... Apr 01 2016
Sanofi and Regeneron Announce Positive Dupilumab Topline Results from Two Phase 3 Trials in... Apr 01 2016
Sanofi successfully prices EUR 1.8 billion bond issue Mar 29 2016
Sanofi poaches AstraZeneca scientist as new research head Mar 29 2016
Sanofi gets shot in the arm from dollar strength Feb 09 2016
First U.S. Zika virus transmission reported, attributed to sex Feb 03 2016
Quest for Zika vaccine widens; Africa, Asia deemed vulnerable Feb 02 2016
France's Sanofi launches Zika virus vaccine research Feb 02 2016
Sanofi launches hunt for Zika vaccine as disease fears grow Feb 02 2016
Zika virus set to spread across Americas, spurring vaccine hunt Jan 25 2016
Sanofi deepens cancer drive with $1.2 bln of deals, Innate jumps Jan 11 2016
Exclusive: Lazard works with Sanofi on $12.7 billion animal health unit deal - sources Nov 27 2015
Sanofi posts 72.5 crore profit Oct 20 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK